Clinical grade purification and expansion of natural killer cells.

Natural killer (NK) cells have been shown to have important functions in anti-tumor responses and therefore have been used as adoptive immunotherapy for cancer. Here, we review the current methods of ex vivo activation, enrichment, expansion, and shipment of clinical NK cell products.

[1]  E. Seifried,et al.  Treatment of patients with advanced cancer with the natural killer cell line NK-92. , 2013, Cytotherapy.

[2]  D. Kaufman,et al.  Clinical‐Scale Derivation of Natural Killer Cells From Human Pluripotent Stem Cells for Cancer Therapy , 2013, Stem cells translational medicine.

[3]  R. V. van Etten,et al.  Autologous stem cell transplant recipients tolerate haploidentical related‐donor natural killer cell–enriched infusions , 2013, Transfusion.

[4]  D. Campana,et al.  Fresh Ex Vivo Expanded Natural Killer Cells Demonstrate Robust Proliferation in Vivo in High-Risk Relapsed Multiple Myeloma (MM) Patients , 2012 .

[5]  Elaine Coustan-Smith,et al.  Large-scale ex vivo expansion and characterization of natural killer cells for clinical applications. , 2012, Cytotherapy.

[6]  R. Handgretinger,et al.  IL-15-stimulated CD3/CD19-depleted stem-cell boosts in relapsed pediatric patients after haploidentical SCT , 2012, Leukemia.

[7]  Juan F. Vera,et al.  Optimization Manufacture of Virus- and Tumor-Specific T Cells , 2011, Stem cells international.

[8]  Harry Dolstra,et al.  Clinical-Grade Generation of Active NK Cells from Cord Blood Hematopoietic Progenitor Cells for Immunotherapy Using a Closed-System Culture Process , 2011, PloS one.

[9]  K. Keyvanfar,et al.  Adoptive Transfer of Escalating Doses of Ex Vivo Expanded Autologous Natural Killer (NK) Cells In Patients with Advanced Malignancies Following Bortezomib Treatment to Sensitize to NK-TRAIL Cytotoxicity , 2010 .

[10]  B. Lindgren,et al.  Allogeneic natural killer cells for refractory lymphoma , 2010, Cancer Immunology, Immunotherapy.

[11]  M. Berg,et al.  Clinical-grade ex vivo-expanded human natural killer cells up-regulate activating receptors and death receptor ligands and have enhanced cytolytic activity against tumor cells. , 2009, Cytotherapy.

[12]  D. Campana,et al.  Expansion of highly cytotoxic human natural killer cells for cancer cell therapy. , 2009, Cancer research.

[13]  B. Barlogie,et al.  Infusion of haplo‐identical killer immunoglobulin‐like receptor ligand mismatched NK cells for relapsed myeloma in the setting of autologous stem cell transplantation , 2008, British journal of haematology.

[14]  J. Wagner,et al.  Good manufacturing practices production of natural killer cells for immunotherapy: a six‐year single‐institution experience , 2007, Transfusion.

[15]  K. Foon,et al.  NK cells in cancer immunotherapy: three decades of discovery. , 2006, Discovery medicine.

[16]  E. Seifried,et al.  Ex vivo Expansion of Highly Purified NK Cells for Immunotherapy after Haploidentical Stem Cell Transplantation in Children , 2005, Klinische Padiatrie.

[17]  D. Campana,et al.  Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells. , 2005, Blood.

[18]  C. Le,et al.  Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. , 2005, Blood.

[19]  E. Seifried,et al.  IL-2 activated NK cell immunotherapy of three children after haploidentical stem cell transplantation. , 2004, Blood cells, molecules & diseases.

[20]  A. Gratwohl,et al.  Purified donor NK-lymphocyte infusion to consolidate engraftment after haploidentical stem cell transplantation , 2004, Leukemia.

[21]  H. Klingemann,et al.  Ex vivo expansion of natural killer cells for clinical applications. , 2004, Cytotherapy.

[22]  H. Ljunggren,et al.  A new method for in vitro expansion of cytotoxic human CD3-CD56+ natural killer cells. , 2001, Human immunology.

[23]  T. Whiteside,et al.  Therapeutic Activity of NK Cells against Tumors , 2001, International reviews of immunology.

[24]  J. Gong,et al.  Characterization of a human cell line (NK-92) with phenotypical and functional characteristics of activated natural killer cells. , 1994, Leukemia.

[25]  W. Boyle,et al.  Isolation of Human Lymphocytes by a Ficoll Barrier Method , 1969, Transfusion.